Related Experiment Videos
[Fat and renal failure--therapeutic aspects]
Klinische Wochenschrift
|August 1, 1982
Summary
Hyperlipidemia in kidney disease patients may increase cardiovascular risk. Treatment options include lifestyle changes, medications like clofibrate, or carnitine for dialysis patients.
Area of Science:
- Nephrology
- Cardiology
- Clinical Pharmacology
Context:
- Hyperlipidemia is frequently observed in patients with chronic renal insufficiency, on dialysis, and post-renal transplantation.
- The reduced high-density lipoprotein (HDL) cholesterol fraction in these patients may elevate cardiovascular complication risk.
Purpose:
- To review the current debate on treating hyperlipidemia in renal disease patients.
- To discuss therapeutic strategies and their efficacy in managing lipid disorders in kidney disease.
Summary:
- Therapeutic approaches include lifestyle modifications (exercise, reduced carbohydrate intake) and pharmacotherapy (clofibrate, bezafibrate).
- Specific dosages are recommended for clofibrate and bezafibrate in patients with renal insufficiency.
- Carnitine supplementation can reduce plasma lipids in patients undergoing regular dialysis.
- Hyperlipidemia in nephrotic syndrome is generally not treated specifically due to associated HDL-cholesterol increases and resolves with remission.
Impact:
- Provides guidance on managing hyperlipidemia in diverse renal patient populations.
- Highlights the importance of considering cardiovascular risk in renal disease.
- Informs clinical decisions regarding pharmacotherapy and lifestyle interventions for lipid management in kidney disease.